San Jose, California (PRWEB) July 21, 2014
Follow us on LinkedIn – GIA is pleased to announce the launch of a major research program analysing the trends impacting the market for “Pediatric Drugs and Vaccines”. Invited to participate in this comprehensive grassroots level global research initiative are senior industry executives, domain experts, technologists and market strategists. The new report to be issued shortly will offer accurate assessment of global market developments including major technologies, trends and challenges, together with descriptive, exploratory, and quantitative analysis of major product and geographic market segments. For details about participation in this primary research program to include your inputs prior to the publication, please click here.
Rise in chronic health conditions in children represents a major factor fuelling demand for pediatric drugs and vaccines. Poor dietary habits, sedentary lifestyles, and lack of exercise are resulting in increased prevalence of obesity, asthma, diabetes, behavioural and learning problems in children. Huge unmet medical needs in this market juxtaposed with saturating market opportunities in geriatric pharmaceuticals, is resulting in a large number of pharmaceutical companies shifting focus to pediatric drug development. Federal level recognition and acceptance of distinct therapeutic needs for pediatric patients is playing an instrumental role in encouraging pediatric drug development programs. Additionally, in an attempt to encourage manufacturers to perform clinical trials for the pediatric population, the FDA and EMA are adopting new regulations and policies. Developments in preclinical safety assessment, better understanding of pharmacological principles in pediatric drug development, and stringent formulation, chemistry, and manufacturing controls, will benefit the development of successful clinical therapeutics for this vulnerable patient population. Future growth in the market will come from pediatric vaccines, hormone therapy drugs, respiratory & allergy drugs, CNS drugs, and anti-infective drugs. Further, sales of other drugs including anti-obesity medicines are expected to grow, following their approval for pediatric use.
The upcoming report will offer coverage on major companies including Abbott Laboratories, GlaxoSmithKline Plc., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi, among others.
In addition, the study will also provide:
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/